IMA401 (Phase Ia)

Phase 1Protein / enzyme

IImmatics Biotechnologies GmbH

IMA401 (Phase Ia) is one of 28 biologic programs targeting Refractory Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory Solid TumorsRecruiting

Refractory Solid TumorsPhase 1

Recruiting

Competition

Competitive Landscape

33 competitors in Refractory Solid Tumors

#DrugCompanyPhaseTrials

Votrient

Novartis

Phase 2

5 2

Opdivo

Bristol-Myers Squibb

Phase 2

3 3

Keytruda

Merck & Co.

Phase 2

3 4

Gemzar

Johnson & Johnson

Phase 2

2 5

Ibrance

Pfizer

Phase 2

1 6

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 7

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

6 8

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 9

Adrucil

EElorac, Inc.

Phase 2

2 10

Camptosar

Pfizer

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Refractory Solid Tumors

NCT05359445

Clinical

Trials by Indication[1]

Refractory Solid Tumors1 trial

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Recruiting·IImmatics Biotechnologies GmbH·Phase 1·NCT05359445·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IMA401 (Phase Ia). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IMA401 (Phase Ia) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IMA401 (Phase Ia). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Immatics Biotechnologies GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 1[1]
Company: IImmatics Biotechnologies GmbH

IMA401 (Phase Ia)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Refractory Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News